Skip to main content
. 2019 Nov 29;9(12):96. doi: 10.1038/s41408-019-0257-x

Table 3.

Basic clinical data of samples without any IGH_V(D)J rearrangement.

Age at Dx (y) MRD_EOI IGH_V(D)J IKZF1 UPN Fusion Response EOI Therapy
17 9.00E-03 del 1–8 37 BCR-ABL1 yes Tx
17.5 9.00E-02 del 4–7 21 CRLF2-IGH LateResp Tx
11 9.00E-02 del 2–8 1 DUX4-IGH LateResp Tx
16 2.00E-02 wt 10 DUX4-IGH pesistent MRD Tx
5 2.00E-03 del 4–7 8 DUX4-IGH Yes Remission
10 7.00E-02 wt 61 EBF-PDGFRB LateResp /COALLa
7.5 4.00E-01 del 2–7 12 EPOR-IGH LateResp TRM
13 2.00E-01 del 4–8 16 EPOR-IGH LateResp Tx
17.5 9.00E-02 del 2–3 13 EPOR-IGH LateResp Tx
16 5.00E-02 del 2–8 69 FOXP1-ABL1 LateResp Tx
12 2.00E-02 wt 72 n.d. LateResp Rel/Tx 2.rem

n.d. not detectable, Rel relapse, Rem remission, Tx Hematopoietic Stem Cell Transplantation

EOI end of induction therapy, TRM treatment related mortality

aoff protocol treatment intensification